Glycomine Overview

  • Founded

  • 2014

Founded
  • Status

  • Private

  • Employees

  • 20

Employees
  • Latest Deal Type

  • Series B

  • Latest Deal Amount

  • $68M

  • Investors

  • 17

Glycomine General Information

Description

Developer of orphan drugs designed to treat rare disorders of metabolism and protein misfolding. The company's drugs combine replacement therapies such as substrates, enzymes, and proteins with intracellular delivery vehicles consisting of bio-nano materials and ligands that target the molecules to the cell interior of clinically relevant organs, enabling physicians to efficiently treat their patients.

Contact Information

Website
www.glycomine.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • MBC BioLabs
  • 733 Industrial Road
  • San Carlos, CA 94070
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Glycomine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 11-Jun-2021 $68M 000.00 00000 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 16-Nov-2016 0000 000.00 000.00 Completed Clinical Trials - Phase 1
2. Accelerator/Incubator 01-Jan-2016 $630K $630K Completed Clinical Trials - Phase 1
1. Accelerator/Incubator Completed Startup
To view Glycomine’s complete valuation and funding history, request access »

Glycomine Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B-2 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 1,337,056 $0.000100 $3.8 $3.8 1x $3.8 1.92%
To view Glycomine’s complete cap table history, request access »

Glycomine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of orphan drugs designed to treat rare disorders of metabolism and protein misfolding. The company's drugs com
Drug Discovery
San Carlos, CA
20 As of 2022
000.00
0000 0000-00-00
00000000000 000.00

000000

g elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
0000000000000
Waltham, MA
00 As of 0000
00000
0000 0000-00-00
000000&0 00000

000000

olor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
0000 000000000
Philadelphia, PA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Glycomine Competitors (53)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Visterra Formerly VC-backed Waltham, MA 00 00000 000000&0 00000
0000000 0000000000 Venture Capital-Backed Philadelphia, PA 00 00000 000000000 00000
000000000 Formerly VC-backed Tucson, AZ 00 000.00 000000&0 000.00
0000000 Venture Capital-Backed Niel, Belgium 00 00000 00000000000 00000
000000000 00000000 Formerly VC-backed New York, NY 00 000.00 00000000 000.00
You’re viewing 5 of 53 competitors. Get the full list »

Glycomine Patents

  • 16

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Glycomine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020252005-A1 Liposomal formulations, and methods of using and preparing thereof Pending 29-Mar-2019 00000000000
CA-3134828-A1 Liposomal formulations, and methods of using and preparing thereof Pending 29-Mar-2019 00000000000
EP-3946365-A1 Liposomal formulations, and methods of using and preparing thereof Pending 29-Mar-2019 00000000000
US-20220184107-A1 Liposomal formulations, and methods of using and preparing thereof Pending 29-Mar-2019 00000000000
US-11045419-B2 Pharmaceutical preparation of carbohydrates for therapeutic use Active 16-Sep-2013 A61K9/1271
To view Glycomine’s complete patent history, request access »

Glycomine Executive Team (8)

Name Title Board Seat Contact Info
Geoffrey Hird Ph.D Chief Technology Officer
Hicham Alaoui Ph.D Chief Scientific Officer
Steven Axon Chief Executive Officer & Board Member
Peter McWilliams Ph.D Chief Business Officer & Board Member
Matt Wilsey Advisor
You’re viewing 5 of 8 executive team members. Get the full list »

Glycomine Board Members (13)

Name Representing Role Since
Bali Muralidhar Ph.D Abingworth Board Member 000 0000
Christopher Starr Ph.D Self Chairman 000 0000
Jackie Grant Ph.D Self Board Member 000 0000
Jason Hafler Ph.D Sanofi Ventures Board Member 000 0000
Jim Trenkle Ph.D Sanofi Ventures Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Glycomine Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Glycomine Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Abingworth Venture Capital Minority 000 0000 000000 0
Asahi Kasei Pharma Venture Capital Corporate Venture Capital Minority 000 0000 000000 0
Mesa Verde Venture Partners Venture Capital Minority 000 0000 000000 0
Mission Bay Capital Venture Capital Minority 000 0000 000000 0
Mission BioCapital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 17 investors. Get the full list »

Ready to get started?

Request a free trial